Holen Sie sich die Stockscreener-App
27.27
0.05%
0.0134
Schlusskurs vom Vortag:
$27.28
Offen:
$27.42
24-Stunden-Volumen:
512.92K
Relative Volume:
0.44
Marktkapitalisierung:
$1.59B
Einnahmen:
$32.87M
Nettoeinkommen (Verlust:
$674.31M
KGV:
2.4002
EPS:
11.36
Netto-Cashflow:
$-330.11M
1W Leistung:
+1.17%
1M Leistung:
-32.89%
6M Leistung:
-18.91%
1J Leistung:
-43.88%
1-Tages-Spanne:
$26.88
$27.64
1-Wochen-Bereich:
$26.88
$28.57
52-Wochen-Spanne:
$22.24
$51.27
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie AGIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
27.30 | 1.59B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.77 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.60 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.54 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.97 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-27 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Agios Pharma stock awaits FDA decision on Pyrukynd as PDUFA date passes - Investing.com UK
Marshall Wace LLP Purchases 163,796 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals' Supplemental NDA for Mitapivat to Treat Thalassemia Still Under FDA Review - marketscreener.com
Agios Pharmaceuticals (AGIO) Awaits FDA Decision on Mitapivat Ap - GuruFocus
Agios Pharmaceuticals says FDA has not issued decision on Agios' sNDA for mitapivat - marketscreener.com
Agios Pharma falls after FDA misses decision deadline on blood-disorder drug filing - TradingView
FDA delays decision on Agios’ thalassemia drug application By Investing.com - Investing.com UK
Agios Pharmaceuticals Provides Update on FDA Review Status for Supplemental New Drug Application of Mitapivat for Thalassemia - Quiver Quantitative
Agios stock falls after FDA delays decision on thalassemia drug By Investing.com - Investing.com UK
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia - The Manila Times
Agios (Nasdaq: AGIO) says FDA mitapivat thalassemia sNDA still under review after Dec. 7 PDUFA goal date - Stock Titan
(AGIO) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Agios Faces A Make-Or-Break Year As Key Drug Decisions Loom - Finimize
How The Latest Trial And FDA Risk Shift The Story For Agios Pharmaceuticals - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC (AGIO) Investigation: Bronstei - The National Law Review
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsAGIO - ACCESS Newswire
How Agios Pharmaceuticals Inc. (8AP) stock trades pre earningsMarket Movement Recap & Daily Profit Focused Stock Screening - Newser
Will Agios Pharmaceuticals Inc. (8AP) stock hit analyst forecasts2025 Support & Resistance & Fast Gaining Stock Reports - Newser
Why Agios Pharmaceuticals Inc. (8AP) stock stays on buy listsPortfolio Update Report & Growth Oriented Trading Recommendations - Newser
How analysts rate Agios Pharmaceuticals Inc. stock todayPortfolio Gains Report & Daily Technical Forecast Reports - Newser
Why Agios Pharmaceuticals Inc. (8AP) stock appears on watchlists2025 Historical Comparison & Real-Time Stock Entry Alerts - Newser
Why Agios Pharmaceuticals (AGIO) Is Down 7.1% After Phase 3 Sickle Cell Win With Mitapivat - Sahm
Europe Autoimmune Hemolytic Anemia Therapeutics Market to hit - openPR.com
How cyclical is Agios Pharmaceuticals Inc. (8AP) stock compared to rivalsJuly 2025 Opening Moves & Low Risk Investment Opportunities - Newser
Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight - GlobeNewswire Inc.
Fisher Asset Management LLC Sells 81,799 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Is Agios Pharmaceuticals Inc. (8AP) stock a top dividend aristocrat candidateWeekly Trading Summary & Weekly Return Optimization Plans - Newser
Published on: 2025-12-03 01:52:18 - Newser
Prudential Financial Inc. Lowers Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
How Agios Pharmaceuticals Inc. (8AP) stock gains from tech spending2025 Breakouts & Breakdowns & Fast Entry and Exit Trade Plans - Newser
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst - MSN
How Agios Pharmaceuticals Inc. (8AP) stock moves on employment dataMarket Risk Summary & Growth Focused Investment Plans - Newser
Published on: 2025-12-02 00:03:25 - Newser
Is Agios Pharmaceuticals Inc a good long term investmentPortfolio Risk Assessment & Minimal Capital Trading Tips - earlytimes.in
Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded by Citigroup to Strong-Buy Rating - MarketBeat
How Agios Pharmaceuticals Inc. stock reacts to Fed rate cutsJuly 2025 Chart Watch & Verified Stock Trade Ideas - BỘ NỘI VỤ
How Agios Pharmaceuticals Inc. stock valuations compare to rivals2025 Biggest Moves & Long Hold Capital Preservation Tips - BỘ NỘI VỤ
A Look at Agios Pharmaceuticals (AGIO) Valuation Following Strong Phase 3 Sickle Cell Trial Results - Sahm
Envestnet Asset Management Inc. Reduces Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Aug Intraday: How strong is Agios Pharmaceuticals Inc. stock balance sheet2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - moha.gov.vn
Agios Pharmaceuticals Inc Stock Analysis and ForecastDividend Aristocrats List & Trusted Financial Advisors at No Cost - earlytimes.in
Intech Investment Management LLC Sells 12,496 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
FY2026 EPS Estimates for AGIO Increased by Cantor Fitzgerald - MarketBeat
Geode Capital Management LLC Boosts Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Does Agios Pharmaceuticals Inc. (8AP) stock trade below intrinsic valueTreasury Yields & Stock Portfolio Risk Management - moha.gov.vn
Citigroup Initiates Coverage on AGIO with a Buy Rating | AGIO St - GuruFocus
Is Agios Pharmaceuticals Inc. stock a safe haven assetProfit Target & Long Hold Capital Preservation Plans - BỘ NỘI VỤ
(AGIO) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Agios falls after mixed data from late-stage trial for sickle cell therapy - MSN
Agios Beats Revenue Forecasts And Eyes PYRUKYND’s Future - Finimize
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Agios Pharmaceuticals Inc-Aktie (AGIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Scadden David | Director |
Nov 12 '25 |
Sale |
43.84 |
200 |
8,768 |
17,603 |
| Gheuens Sarah | Chief Medical Officer |
Nov 11 '25 |
Option Exercise |
25.01 |
2,454 |
61,375 |
64,181 |
| Gheuens Sarah | Chief Medical Officer |
Nov 11 '25 |
Sale |
43.78 |
2,454 |
107,436 |
61,727 |
1.37%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):